key: cord-0771608-vutvtqf5
authors: Ding, Yu; Fei, Yiyan; Lu, Boxun
title: Emerging New Concepts of Degrader Technologies
date: 2020-04-23
journal: Trends Pharmacol Sci
DOI: 10.1016/j.tips.2020.04.005
sha: 78dfaeda3a76ce5c3206057e79dcdf568375ddb1
doc_id: 771608
cord_uid: vutvtqf5

Abstract The traditional drug discovery focuses on identifying direct inhibitors of target proteins. This approach typically relies on a specific measurable biochemical readout and amenable binding sites of which the occupancy directly influences the target protein’s function. These requirements preclude many disease-causing proteins from being “druggable” targets, and these proteins are categorized as “undruggable”. The proteolysis-targeting chimera (PROTAC) technology provides powerful tools to degrade these “undruggable” targets and has become a promising approach for drug discovery. However, the PROTAC technology may have limitations and emerging new degrader technologies may greatly broaden the spectrum of targets that could be selectively degraded by harnessing another major degradation pathway in cells. Here we review a few key emerging technologies that exploit the lysosomal degradation pathway and discuss their potential applications as well as limitations.

J o u r n a l P r e -p r o o f

Cullin-F box complex, leading to ubiquitination and degradation of MetAP-2 in a dose-dependent manner. However, the MetAP-2 covalently-bound moiety was a peptide, hindering the further application towards therapeutic research due to its large molecule size that leads to poor cellular penetration. In 2008, a cell-permeable PROTAC molecule linking the non-steroidal androgen receptor ligand (SARM) and the MDM2 ligand nutlin with a PEG-based linker was synthesized [19] . This PROTAC molecule can induce the ubiquitination of the androgen receptor and its subsequent degradation by the proteasome. This PROTAC system is based on MDM2, which is the major E3 ligase ubiquitinating the tumor suppressor protein p53 [20] . The nutlins family consists of small molecules that bind to the p53-binding pocket of MDM2 and thus competitively inhibit the interaction between p53 and MDM2 [21] , inducing possible off-target effects. The nutlins was further improved to RG7112 [22] and RG7388 [23] , with superior potency and selectivity. In 2010, a new PROTAC system using the cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase was established. Hashimoto and colleagues verified that the hybrid molecule coupling the cIAP1 ligand methyl bestatin and the ligand of CRABPs can induce degradation of CRABP-II in cells via the proteasomal pathway [24] . In 2015, the Bradner group has first established another important PROTAC system based on cereblon (CRBN) [25] . CRBN was initially identified as the primary mediator of the teratogenic activity of thalidomide by Handa and colleagues [26] . The immunomodulatory drugs (IMiDs) including thalidomide and its derivatives such as lenalidomide and pomalidomide were later on utilized to treat multiple myeloma [27] . These IMiDs were further reported to interact with the CRBN-DNA damage binding protein-1 (DDB1) complex [28] . Shortly after, a series of PROTAC molecules consist of CRBN-binding IMiD connected with small-molecule ligands of different POIs were designed and their degrader capability was verified [25, 29, 30] . For example, the JQ1-penalidomide chimeric compounds can selectively degrade the BRD4 protein via CRBN [25] . Another PROTAC system, the VHL-PROTAC system based on HIF1-α derived peptide was initially introduced in 2004 [31] .

In 2015, the replacement of the VHL-targeting peptide by hydroxyproline-like small molecules J o u r n a l P r e -p r o o f 6 / 23 significantly improved the affinity and specificity of the VHL-PROTAC system [32] , greatly expanding its applications. Currently, while there are over 600 known human E3 ligases, the established PROTAC systems rely on less than ten of them, of which the most widely used are CRBN [28] , Von Hippel Lindau (VHL) [31] , cIAP [24] , and MDM2 [19] discussed above.

One desiring property of PROTACs is that they catalytically involve in multiple rounds of target protein degradation [29, 32, 33] . Therefore, the degradation induced by PROTACs is sub-stoichiometric, i.e. one PROTAC molecule is able to induce the ubiquitination and degradation of multiple POI molecules. The catalytic nature of PROTACs provides potential strong degradation power with relatively low concentrations, and it is sometimes desired to have temporal and spatial control of this power. Recent studies have developed controllable PROTACs, such as photoswitchable azobenzene-PROTACs (Azo-PROTACs) and photo-caged PROTACs (pc-PROTACs) [34, 35] . Azo-PROTACs are light-controlled small-molecule tools for protein knockdown in cells. The light-induced configuration change can switch the active state to induce protein degradation activity, which can be reversely controlled by light exposure in intact cells [34] . For pc-PROTACs, photo-removable blocking groups were added to a degrader of Brd4, and the resulting molecule showed potent degradation activity in live cells only after light irradiation [35] .

While the PROTAC field is booming, a number of potential limitations of PROTAC have been identified: PROTAC molecules often have high molecular weights (over 800 Da) and relatively high polar surface area, likely leading to low solubility, poor cell permeability, low oral bioavailability as well as blood-brain barrier penetration. The PROTAC's effects are dependent on specific E3 ligase subunits and thus are influenced by their expression, limiting their application in certain cell types. The dependence on specific E3 ligase subunits may also cause resistance in cancer cells following chronic PROTAC treatment [36] . Finally, PROTAC molecules induce POIs' degradation via the proteasome, which has limited capability of proteins with expanded repeat sequences, protein aggregates, and other non-protein molecules [37] . 

As discussed above, while the PROTAC technology is extremely promising, its dependence on the expression of specific E3 ligases and the proteasomal pathway may limit its potential application in certain cell types or targeting certain proteasome-resistant proteins.

Encouragingly, novel concepts emerged very recently around the lysosomal degradation pathway, which is the other major degradation pathway that is independent of the proteasome [38] . The lysosomal degradation pathway includes the endosome-lysosome pathway and the autophagy pathway (reviewed in [39, 40] ). The endosome-lysosome pathway is mediate through a series of transformation between several membrane-bound intracellular compartments: the endocytosed material is incorporated and proceeds through the early endosomes, the endosome carrier vesicle, the late endosome and the lysosome for subsequent hydrolysis [39] . The autophagy pathway starts with an isolated membrane structure called a phagophore, which is derived from lipid bilayer with lipidated LC3 proteins [41] . This phagophore expands to engulf intracellular cargoes (autophagy substrates), including proteins and other biomolecules or even organelles, thereby sequestering them in a double-membraned vesicle called the autophagosome [40] . The loaded autophagosome matures through fusion with the lysosome, leading to degradation of the cargoes.

Thus, both the endosome-lysosome pathway and the autophagy pathway have degradation capabilities, and new concepts have been designed and demonstrated to harness each of these pathways for selective degradation.

The LYTAC (LYsosome TArgeting Chimera) technology is a promising strategy to hijack the endosome-lysosome pathway to degrade POIs, currently published as a preprint paper without peer review [42] . Excitingly, LYTAC molecules may work on extracellular proteins as well as membrane-bound proteins such as EGFR [42] . These types of proteins are typically resistant to PROTAC, which mainly targets intracellular proteins. An LYTAC molecule consists of an antibody to a specific POI, with a 20-or 90-mer of mannose-6-phosphate (M6P) covalently attached to this antibody. M6P is a glycan mark to target proteins for degradation by binding to J o u r n a l P r e -p r o o f 8 / 23 the cation-independent M6P receptor (CI-M6PR) [42] . Thus, the M6P-conjugated antibodies, i.e. the LYTAC molecules, are recognized by this endogenous system for lysosomal degradation of glycosylated proteins, bring the POIs together with them to the lysosome for degradation. In certain cases, the M6P-conjugated antibodies could be replaced by CI-M6PR's polypeptide ligands conjugated to a small molecule binding to the POI. The authors confirmed that a polypeptide with multiple ligands for CI-M6PR attached to biotin (a high affinity binder to Avidin) targets the extracellular NeutrAvidin protein to the endosomes and lysosomes [42] . The advantage of the LYTAC technology is that it enables degradation of both extracellular and membrane POIs, and it utilizes a ubiquitously expressed endogenous degradation pathway. The major limitation is that LYTAC molecules are quite large, and thus lose the desired properties of small-molecule compound drugs. The antibody or polypeptide nature of the molecules may also induce immune responses [43] .

The LYTAC technology targets extracellular and/or membrane POIs to the endosomelysosome pathway, and it is inapplicable for cytosolic proteins, which could be the targets of autophagy. Thus, the autophagy-targeting degrader technologies are highly desired for cytosolic POIs, especially those resistant to PROTAC molecules. While there are several different types of autophagy, it typically refers to macroautophagy, a multistep cellular process in which cargo proteins are engulfed into autophagosomes formed by intracellular double-membranes containing lipidated LC3 proteins [41] . Meanwhile, autophagy receptors such as SQSTM1/p62 may recognize Lys63 (K63) poly-ubiquitinated protein cargoes and shuttle them to autophagosomes for subsequent clearance [44] , and this process is referred to as "selective autophagy" [45, 46] . Two independent new degrader technologies harnessing the autophagy pathway have been reported very recently.

The autophagy-targeting chimera (AUTAC) system utilizes a similar design as the PROTAC technology [47] . Both AUTAC and PROTAC molecules function via ubiquitination.

However, instead of tethering the POIs to an E3 ligase subunit and triggering K48-poly-J o u r n a l P r e -p r o o f 9 / 23 ubiquitination, AUTAC molecules trigger K63-poly-ubiquitination, which is recognized by the selective autophagy pathway to degrade the target POIs. An AUTAC molecule contains a degradation tag (guanine derivatives) and a ligand of the POI to provide target specificity. The degradation tag mimics S-Guanylation, a posttranslational modification of Cys-cGMP adducts formed by treatment of 8-nitro-cGMP or similar compounds [48] . The authors suggest that S-Guanylation is a standalone tag that destines the substrate protein for selective autophagy by inducing its K63-poly-ubiquitination [47] . The authors showed encouraging results that AUTAC molecules are capable of degrading POIs as well as cellular organelles such as damaged mitochondria.

The design of AUTAC cleverly utilizes a process that defends cells against invading group A Streptococcus [49] . Meanwhile, AUTAC molecules function through a complicated multiple-step processes that need to be further clarified. In particular, the molecular mechanism mediating the S-Guanylation triggered K63-ubiquitination of POIs needs to be resolved, and the efficiency and potential off-target effects of this pathway needs to be determined. This information is required to clarify which proteins are required for the AUTAC system, how the AUTAC system may be influenced by each mediator, and whether hijacking this pathway may cause changes of other cellular functions. In addition, whether AUTAC molecules may influence the selective autophagy process per se and whether they are functional in vivo need to be investigated.

The concept of autophagosome-tethering compound (ATTEC) illustrates a more direct strategy to harness autophagy to degrade POIs [50, 51] . Different from PROTAC and AUTAC, ATTEC molecules are independent of ubiquitination. Instead, ATTEC molecules tether the POI with the autophagosomes through their direct binding to the POI and the key autophagosome protein LC3. The proof-of-concept study established a high-throughput screening strategy to identify such compounds targeting the mutant HTT protein (mHTT), which is the Huntington's disease-(HD-) causing protein with an expanded polyglutamine (polyQ) stretch [52] . The study J o u r n a l P r e -p r o o f 10 / 23 demonstrated that these compounds can degrade mHTT both in cells and in vivo in the animal models, and can rescue HD-relevant phenotypes [51] . The study also confirmed that these compounds can target mHTT to the autophagsomes for subsequent degradation without influencing the autophagy activity per se. By the counter-screen against binders of the wild-type HTT protein (wtHTT), the discovered ATTEC molecules are allele-selective, i.e., they degrade mHTT without influencing the wtHTT level. In vitro experiments revealed that these compounds specifically interact with the expanded polyQ stretch, possibly by recognizing its unique structural feature that is different from short polyQ stretch [53, 54] . Thus, the discovered ATTEC molecules are also capable of degrading other disease-causing polyQ proteins, such as mutant ATXN3, which causes spinocerebellar ataxia type III [51] . Some of the discovered ATTEC molecules are able to pass the blood-brain barrier and function at ~100 nM concentrations [51] , providing encouraging entry points for drug discovery. By interacting with the autophagosome protein LC3 directly and bypassing the ubiquitination process, ATTEC molecules may have great potential in degrading different types of cargoes, including autophagy-recognized non-protein cargoes such as DNA/RNA molecules, damaged organelles, etc., via a direct mechanism. ATTEC molecules do not influence global autophagy activity [51] , whereas it remains to be elucidated if AUTACs do. It is important not to perturb global autophagy, because this may minimize nonspecific degradation of functional proteins and organelles.

Further studies are desired to further develop ATTEC. The compound compartments that interact with LC3 remain to be resolved for ATTEC molecules. Unlike PROTAC, LYTAC, and AUTAC, the discovered ATTEC molecules targeting mHTT have very small sizes compared to the relatively large chimeric compounds with a linker between two separate chemical moieties that interact with the POI and the degradation machinery, respectively. Whether they could be developed to functional chimeric molecules by attaching the LC3-binding "warhead" to POIs'

binding compounds remains to be tested. On the other hand, these small compounds may have the advantage of having better drug properties. 

The emerging new concepts of degrader technologies, especially those novel ones around the autophagic/lysosomal degradation pathway may greatly expand the landscape of the applications of degrader technologies. While current studies were mainly focusing on pathogenic proteins, these new concepts could also be explored for their capabilities to degrade pathogenic targets other than soluble proteins, such as protein aggregates, DNA/RNA molecules, peroxisomes, ribosomes, damaged mitochondria or even microbial pathogens. Here we briefly discuss the future possibilities of using these concepts to degrade some of these targets as potential examples of future applications of these technologies.

Many neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, are associated with the formation of protein aggregates/oligomers by misfolded proteins [55, 56] . Clearing these protein aggregates/oligomers without affecting their wild-type counterparts is likely a promising drug discovery paradigm. Given the poor capability of the proteasome in degrading these aggregates/oligomers [37] , autophagy hijacking degraders may have a better capability to target protein aggregates for selective degradation, at least in theory. Consistent with this, one of the discovered ATTEC molecules reduced mutant HTT aggregates significantly [51] . Given that most of the relevant diseases are neurological, the molecules with high lipid solubility and a molecular weight under 500 Da are desired, because they are expected to have a higher chance to cross the blood-brain barrier via passive diffusion [57] . Thus, degraders with smaller molecular weights may have better chance to be developed into drug candidates for the treatment of neurodegeneration. Interestingly, Tau degrader was J o u r n a l P r e -p r o o f recently reported based on the PROTAC system [58] . The compounds efficiently degraded neurodegeneration-related soluble Tau protein, but the Tau aggregates/tangles were not tested [58] . These Tau species might be degraded more efficiently by emerging lysosome-based technologies. Neurodegenerative disorders may also lead to altered lysosome-related functions.

Taking Huntington's disease as an example, the mainstream evidence showed increased presence of endocytic and autophagic compartments [59] [60] [61] [62] and reduced cargo/mHTT recognition [54, [63] [64] [65] . This further justifies enhancing the recognition of pathogenic proteins by degrader technologies such as ATTEC. Meanwhile, for certain diseases with severe lysosomal deficits, correcting the lysosomal function per se is probably more important.

The RNA molecules could be directly recognized by a lysosomal membrane protein, LAMP2C, which load them into the lysosomes for degradation [66] . Further studies revealed that a putative RNA transporter SIDT2 mediates the RNA translocation across the lysosomal membrane [67, 68] . Thus, scientists may screen for high-affinity binding molecules of LAMP2C or SIDT2 and attach them to antisense oligonucleotides or small molecules specifically binding to the target RNA. These chimeric molecules may selectively degrade the target RNA and knock down its encoded pathogenic proteins. This may provide a novel degrader technology for RNA, in addition to the recent nuclease-targeting RNA degrader technology developed by the Disney group [69] . For the DNA molecules, the clearance of cytosolic DNA molecules under pathological conditions is highly desired. Cyclic GMP-AMP (cGAMP) synthase (cGAS) detects infections or tissue damage by binding to microbial or self DNA in the cytoplasm [70] . Upon binding to the DNA, cGAS produces cGAMP that binds to and activates the adaptor protein STING [71] , which induces LC3 lipidation and activates autophagy [72] . The cGAMP-induced autophagy is critical for the clearance of DNA and viruses in the cytosol [72] . This provides a promising possibility of using the autophagy-targeting degrader technologies to enhance the clearance of these DNA molecules and their relevant pathogens or damaged cellular components.

Since the cytosolic DNA could not be ubiquitinated, the suitable degrader technology here is J o u r n a l P r e -p r o o f 13 / 23 probably ATTEC. Scientists may use the ATTEC concept to design molecules consisting of the target DNA binding molecule attached to the LC3-binding chemical moiety, and these chimeric ATTEC molecules may tether the DNA to LC3 for subsequent autophagic degradation.

Bacterial and viral infections present a severe global threat to healthcare. While the antibiotics treatment has obtained enormous success, new therapeutic approaches are desired due to the rise of antibiotic-resistant infections and the dearth of new antibiotics in the pipeline [73] .

Selective autophagy is the major intracellular pathway that targets intracellular pathogens to lysosomes for degradation, and the process is referred to as xenophagy [74] . Thus, autophagylysosome degrader technologies such as ATTEC or AUTAC could be used to target key proteins of the pathogen, leading to enhanced clearance of them via xenophagy. This approach may provide synergistic effects with xenophagy enhancement approaches that have been studied recently to control bacterial infection [75] . Another potential strategy is to target the microbial DNA/RNA to autophagic degradation by ATTEC as discussed in the previous paragraph. The pathogen COVID-19 responsible for the recent pneumonia outbreak could be targeted by the design above as well [76] (see "Outstanding Questions"). Meanwhile, many pathogens have evolved ways to subvert or exploit this defense mechanism, minimizing the actual effectiveness of xenophagy in innate immunity [73, 77] . A better understanding of the complicated relationship between autophagy and microbial pathogens will provide better opportunities to combine novel degrader technologies with xenophagy enhancement approaches to achieve optimal therapeutic effects.

Emerging new concepts of degrader technologies have been designed to harness the relatively non-specific lysosomal degradation pathway for selective degradation of the POIs.

These concepts greatly expand the landscape of therapeutic targets and provide exciting novel approaches of potential therapeutic benefits. LYTACs utilize a glycan tag to mark extracellular POI for intracellular lysosomal degradation following receptor mediated internalization. AUTACs cleverly exploit small-molecule mimics of S-Guanylation to selectively tag POI with K63 ubiquitination and induce their lysosomal degradation via selective autophagy. On the other hand, ATTECs exploit lipidated LC3 to directly tether polyQ proteins to growing autophagosomes to facilitate their selective removal via autophagy. Meanwhile, they have critical concerns to be addressed before maturing to established technologies.

The specificity and potential off-target effects need to be clarified for these technologies (see "Outstanding Questions"). Proteomics studies have been performed for ATTEC in cellular and tissue samples [51] , while such studies for LYTAC and AUTAC are currently missing.

Besides the proteomics studies measuring the steady-state protein levels, researchers may consider investigating whether the compounds interact with proteins other than their designated targets. Scientists may pull-down the compound-binding proteins in cell or tissue lysates and perform proteomics analysis of the pull-down samples to reveal their potential off-target binding partners. In addition, whether these technologies are catalytic and may function substoichiometrically need to be clarified (see Outstanding Questions). In theory, AUTAC and ATTEC could be catalytic because the small molecules such as AUTAC and ATTEC could be recycled after lysosomal degradation of the target proteins, but this needs to be further tested and validated. LYTAC molecules are likely non-catalytic because of its current large biomolecular nature. The non-catalytic nature of the compounds' function may lead to less efficient and yet more controllable degradation compared to catalytic technologies.

There are also specific concerns to be addressed for each of these emerging technologies (see Outstanding Questions). The large LYTAC molecules are desired to be reduced to small molecules for easier delivery and prevention of immune responses. To achieve this, scientists may identify small molecules binding to CI-M6PR by screening or structure-based design. The addressed by interactome studies for protein recognizing this modification, or biochemical screening for modifiers of S-guanylation-induced K63-poly-ubiquitination. The potential influence on autophagy by AUTAC also needs to be tested. Compared to LYTAC and AUTAC studies, the biological effects of ATTEC molecules have been investigated relatively thoroughly.

Meanwhile, the atomic level structural information for the compound-protein interfaces is critical for ATTEC and remains to be solved. Chimeric ATTEC molecules also need to be designed and (B) The schematic illustration of AUTAC. AUTACs bind to the POI and add a degradation tag mimicking S-Guanylation, a posttranslational modification that triggers the K63-polyubiquitination of POI. The POI is then recognized by the autophagy receptor SQSTM1/p62 protein and recruited to the selective autophagy pathway for degradation. For the AUTAC molecule, the "G" pentagon represents the chemical moiety mimicking S-Guanylation and the linked pacman shape represents the targeting recognizing part.

(C) The schematic illustration of ATTEC. ATTECs interact with both the POI and LC3, tethering the POI to the phagophores or autophagosomes directly for subsequent autophagic degradation.

Shaping proteostasis at the cellular, tissue, and organismal level

Autophagy induction as a therapeutic strategy for neurodegenerative diseases

Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases

Genome-editing Technologies for Gene and Cell Therapy

Antisense oligonucleotides in therapy for neurodegenerative disorders

Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins

Identification of Hydrophobic Tags for the Degradation of Stabilized Proteins

Inhibitor mediated protein degradation

Boc3Arg-Linked Ligands Induce Degradation by Localizing Target Proteins to the 20S Proteasome

Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling

PROTACs-a game-changing technology

Targeted protein degradation: expanding the toolbox

PROTACs: great opportunities for academia and industry

Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery

Degradation of proteins by PROTACs and other strategies

Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation

Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics

Mdm2 association with p53 targets its ubiquitination

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development

Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins

Phthalimide conjugation as a strategy for in vivo target protein degradation

Identification of a primary target of thalidomide teratogenicity

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL

Chemical genetic control of protein levels: selective in vivo targeted degradation

Catalytic in vivo protein knockdown by small-molecule PROTACs

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation

Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown

Light-Induced Protein Degradation with Photocaged PROTACs

Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes

Integration of clearance mechanisms: the proteasome and autophagy

Endocytosis and autophagy: exploitation or cooperation?

Endolysosomal proteolysis and its regulation

Autophagy: basic principles and relevance to disease

LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing

Lysosome Targeting Chimeras (LYTACs) for the Degradation of Secreted and Membrane Proteins

Antigenicity and immunogenicity of synthetic peptides

A role for ubiquitin in selective autophagy

Selective autophagy mediated by autophagic adapter proteins

The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alfy

AUTACs: Cargo-Specific Degraders Using Selective Autophagy

Protein S-guanylation by the biological signal 8-nitroguanosine 3',5'-cyclic monophosphate

Autophagy defends cells against invading group A Streptococcus

ATTEC: a potential new approach to target proteinopathies

Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds

Huntington's disease

Conformation-dependent recognition of mutant HTT (huntingtin) proteins by selective autophagy

A toxic mutant huntingtin species is resistant to selective autophagy

Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases

The roles of intracellular protein-degradation pathways in neurodegeneration

Drug transport across the blood-brain barrier

Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

Huntingtin localization in brains of normal and Huntington's disease patients

Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy

Autophagosome-like vacuole formation in Huntington's disease lymphoblasts

Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease

Potential function for the Huntingtin protein as a scaffold for selective autophagy

Huntingtin functions as a scaffold for selective macroautophagy

Discovery of a novel type of autophagy targeting RNA

Lysosomal putative RNA transporter SIDT2 mediates direct uptake of RNA by lysosomes

Cytosolic domain of SIDT2 carries an arginine-rich motif that binds to RNA/DNA and is important for the direct transport of nucleic acids into lysosomes

Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer

Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway

Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA

Autophagy induction via STING trafficking is a primordial function of the cGAS pathway

Bacterial Pathogens versus Autophagy: Implications for Therapeutic Interventions

Shigella phagocytic vacuolar membrane remnants participate in the cellular response to pathogen invasion and are regulated by autophagy

Enhanced Autophagy Contributes to Reduced Viral Infection in Black Flying Fox Cells

A new coronavirus associated with human respiratory disease in China

Escape of intracellular Shigella from autophagy

How do we improve the overall pharmacokinetic profile of PROTAC molecules? 2. What is the overall specificity of emerging degrader technologies, including LYTAC, AUTAC and ATTEC?

What is the molecular mechanism via which S-Guanylation causes K63-ubiquitation?

Does AUTAC influence selective autophagy per se or other cellular pathways?

What is atomic level structural information for the compound-protein interfaces between ATTEC and LC3?

Are the chimeric ATTEC molecules designed by attaching an LC3-interacting chemical moiety to a small molecule ligand of the target protein effective degraders?

Are LYTAC, AUTAC and ATTEC catalytic or non-catalytic?

Can we utilize the emerging new concepts of degrader technologies to degrade nonprotein targets? 10. Can we utilized ATTEC or AUTAC to target COVID-19 by degrading its key protein or RNA?

The authors would like to thank the National Natural Science Foundation of China (81925012, 81870990, 31961130379) and the Newton Advanced Fellowship from Academy of Medical Sciences (NAF\R1\191045) for funding supports.

The authors claim no conflict of interest.

Picchi, A. The cost of Biogen's new drug: $750,000 per patient. https://www.cbsnews.com/news/the-cost-of-biogens-new-drug-spinraza-750000per-patient/